FIRE Funds Income Target ETF FIRI 深 沪
等待开盘 09-06 09:30:00 美东时间
19.075
+0.065
+0.34%
华盛通- 最 高19.22
- 今 开19.16
- 成交量 3317股
- 最 低 19.0599
- 昨 收 19.01
- 总市值 123.99万
- 52周最高 19.22
- 市盈率 静 --
- 换手率 5.10%
- 52周最低 17.848
- 委 比 0.00%
- 总股本 6.50万
- 历史最高 19.22
- 量 比 0
- 振 幅 0.84%
- 历史最低 17.9284
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AIM ImmunoTech Announces Company Update Including Mid-Year Report Of Ampligen In Combination With AstraZeneca's Imfinzi For Treatment Of Pancreatic Cancer Demonstrating Signs Of Both No Significant Toxicity And Superior PFS And OS.Company Also Bolstered Cash Position To Fund Operations For ~12 Months
Primary focus on pancreatic cancerMid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both
08-04 21:06
Why Is Micro-Cap AIM ImmunoTech Stock Surging?
AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients.
07-28 23:12
AIM ImmunoTech Announces Mid-Year Data From Phase 2 DURIPANC Trial Of Ampligen And AstraZeneca's Imfinzi In Metastatic Pancreatic Cancer Patients Post-FOLFIRINOX
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with
07-28 21:03
Xenetic Biosciences Announces First Patient Dosing In Exploratory Clinical Study Of Systemic DNase I In Combination With FOLFIRINOX For Advanced Or Metastatic Pancreatic Cancer
Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNessCompany evaluating systemic recombinant human DNase I (DNase I) in combination with
07-08 21:04
石药集团现涨近4% 同意授予Cipla在美销售伊立替康脂质体注射液独家许可
石药集团（01093）股价现涨3.68%，现报5.92港元，成交额2.03亿港元。 5月15日，石药集团发布公告，集团已与Cipla USA， Inc．（...
05-16 10:57
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the fi...
05-02 04:01
FDA批准百时美施贵宝(BMY.US)Opdivo+Yervoy联合治疗结直肠癌
百时美施贵宝表示，FDA已批准其重磅PD-1抑制剂Opdivo联合CTLA-4靶向抗体Yervoy用于治疗MSI-H或dMMR表型的转移性结直肠癌(mCRC)成人和儿童患者。
04-09 14:48
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, March 8, 2025 /PRNewswire/ -- As the global cancer crisis intensifies, the demand for breakthrough t...
03-08 20:33
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- USA News Group News Commentary – Now that World Cancer Day (Feb. 4) has com...
02-27 23:04
